Moderna stock extends decline after leaked data on melanoma vaccine trial

What happened: Moderna (MRNA) fell nearly 2% on Friday, extending a second day of declines after leaked data from a late-stage trial of its personalized melanoma vaccine. Merck (MRK), its partner, confirmed the results came out early. Key numbers: Stock fell as much as 26% Thursday, closing down more than 17%, its worst day since Aug. 20. Why it matters: The leaked figures, though not bad, failed to impress Wall Street, which had grown cautious after the stock's rally this year. Shares are increasingly valued on cancer treatment potential rather than the declining COVID-19 vaccine business. Market: -2.0% today ($144.33), +36.6% YTD, 0.2x vol — as of 14:33 UTC Coverage: 5 outlets in 24h

Moderna (MRNA) fell nearly 2% on Friday, extending a second day of declines after leaked data from a late-stage trial of its personalized melanoma vaccine. Merck (MRK), its partner, confirmed the results came out early.

The leaked figures, though not bad, failed to impress Wall Street, which had grown cautious after the stock's rally this year. Shares are increasingly valued on cancer treatment potential rather than the declining COVID-19 vaccine business. Market: -2.0% today ($144.33), +36.6% YTD, 0.2x vol — as of 14:33 UTC